Epigenetic dysregulation of TET2 in human glioblastoma

María G. García; Antonella Carella; Rocío G. Urdinguio; Gustavo F. Bayón; Virginia Lopez; Juan Ramón Tejedor; Marta I. Sierra; Estela García-Toraño; Pablo Santamarina; Raúl F. Perez; Cristina Mangas; Aurora Astudillo; M. Daniela Corte-Torres; Inés Sáenz-de-Santa-María; María-Dolores Chiara; Agustín F. Fernández; Mario F. Fraga

doi:10.18632/oncotarget.25406

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Epigenetic dysregulation of TET2 in human glioblastoma

María G. García, Antonella Carella, Rocío G. Urdinguio, Gustavo F. Bayón, Virginia Lopez, Juan Ramón Tejedor, Marta I. Sierra, Estela García-Toraño, Pablo Santamarina, Raúl F. Perez, Cristina Mangas, Aurora Astudillo, M. Daniela Corte-Torres, Inés Sáenz-de-Santa-María, María-Dolores Chiara, Agustín F. Fernández and Mario F. Fraga _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:25922-25934. https://doi.org/10.18632/oncotarget.25406

Metrics: PDF 2135 views | HTML 3019 views | ?

Abstract

María G. García1,2, Antonella Carella1,2, Rocío G. Urdinguio2, Gustavo F. Bayón1, Virginia Lopez2, Juan Ramón Tejedor1,3, Marta I. Sierra1, Estela García-Toraño1, Pablo Santamarina1, Raúl F. Perez1, Cristina Mangas1, Aurora Astudillo4, M. Daniela Corte-Torres5, Inés Sáenz-de-Santa-María6, María-Dolores Chiara6, Agustín F. Fernández1,3 and Mario F. Fraga2

1Institute of Oncology of Asturias (IUOPA), HUCA, Universidad de Oviedo, Oviedo, Spain

2Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo, El Entrego, Asturias, Spain

3Fundación para la Investigación Biosanitaria de Asturias (FINBA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Asturias, Spain

4Department of Pathology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain

5Biobanco del Principado de Asturias, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain

6Otorhinolaryngology Service, Hospital Universitario Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, CIBERONC, Oviedo, Spain

Correspondence to:

Mario F. Fraga, email: [email protected]

Agustín F. Fernández, email: [email protected]

Keywords: 5-hydroxymehtylcytosine; glioblastoma; TET2; epigenetics; DNA methylation

Received: September 08, 2017 Accepted: April 28, 2018 Published: May 25, 2018

ABSTRACT

Ten-eleven translocation (TET) enzymes are frequently deregulated in cancer, but the underlying molecular mechanisms are still poorly understood. Here we report that TET2 shows frequent epigenetic alterations in human glioblastoma including DNA hypermethylation and hypo-hydroxymethylation, as well as loss of histone acetylation. Ectopic overexpression of TET2 regulated neural differentiation in glioblastoma cell lines and impaired tumor growth. Our results suggest that epigenetic dysregulation of TET2 plays a role in human glioblastoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25406

Publication Alerts

Research Papers:

Epigenetic dysregulation of TET2 in human glioblastoma

Abstract